男性乳腺癌新辅助化疗1例并文献复习  

Neoadjuvant chemotherapy in male breast cancer:A case report and literature review

作　　者：曹欣华 吕建鑫[1] 胡浩霖[1] 张亚男[1] CAO Xinhua;LÜJianxin;HU Haolin;ZHANG Yanan(Breast Center,Zhongda Hospital,Southeast University,Nanjing 210009,China)

机构地区：[1]东南大学附属中大医院乳腺中心,南京210009

出　　处：《临床与病理杂志》2020年第8期2220-2224,共5页Journal of Clinical and Pathological Research

摘　　要：男性乳腺癌(male breast cancer,MBC)属罕见疾病,约占所有乳腺癌的1%。其发病原因与乳腺癌家族史、BRCA基因突变等有关。目前的治疗手段主要包括手术、化疗、放疗及内分泌治疗。本文回顾性分析1例男性乳腺癌(male breast cancer,MBC)新辅助化疗及手术的相关临床资料及相关文献。患者男,乳腺癌术前穿刺诊断明确,行5周期新辅助化疗后疗效评价为部分缓解(partial response,PR),后行手术治疗。随访至2019年10月28日,未见转移及复发。Male breast cancer(MBC)is rare and accounts for approximately 1%of breast cancer.It is closely related with breast cancer family history and BRCA gene mutation.The treatments mainly include surgery,chemotherapy,radiotherapy and endocrine therapy.We analyzed the clinical data of a patient with male breast cancer retrospectively,and reviewed interrelated literatures.The male patient with breast cancer received neoadjuvant chemotherapy,after five cycles the response of the tumour was partial response.Then the patient accepted surgery.We didn’t find recurrence or metastasis,and the patient didn’t feel uncomfortable up to 28 October 2019.

关 键 词：男性 乳腺癌 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤]